首页 | 本学科首页   官方微博 | 高级检索  
检索        

增强型Trop2-CD40L病毒样颗粒疫苗的制备、纯化及活性研究
引用本文:王 琳,王 希,杨 铭,李 岩,董 轲,张惠中.增强型Trop2-CD40L病毒样颗粒疫苗的制备、纯化及活性研究[J].现代检验医学杂志,2016,0(4):1-4,9.
作者姓名:王 琳  王 希  杨 铭  李 岩  董 轲  张惠中
作者单位:第四军医大学唐都医院临床实验与检验科,西安 710038
摘    要:目的 获得嵌合免疫增强佐剂CD40配体(CD40L)的Trop2-CD40L病毒样颗粒(VLPs)疫苗,为后续探究VLPs在肿瘤治疗中的免疫原性及免疫保护作用奠定基础。方法 通过重叠延伸PCR方法扩增以Trop2为靶点、嵌合免疫佐剂CD40L的Trop2-CD40L融合基因,构建杆状病毒表达载体pFastbacTM /Trop2-CD40L,并转化大肠埃希菌E.coli DH10bac,提取杆粒并经PCR鉴定成功命名为Trop2-CD40L Bacmid,后者转染Tn5昆虫细胞获得重组病毒Trop2-CD40L rBV,与Gag rBV共感染昆虫细胞制备重组病毒样颗粒,透析浓缩后蔗糖密度梯度离心纯化,Western Blot鉴定VLPs目的蛋白表达、电镜观察所制备VLPs形态,Cytokine ELISA方法检测Trop2-CD40L VLPs体外生物学活性。结果 成功扩增了Trop2-CD40L融合基因,通过杆状病毒表达系统、借助SIV Gag衣壳蛋白装配特点成功制备了增强型Trop2-CD40L 病毒样颗粒,与Trop2 VLPs比较具有更好的生物学活性,差异具有统计学意义(t=7.266,,P<0.05)。结论 制备出具有一定生物学活性的增强型Trop2-CD40L病毒样颗粒,证实了CD40L作为免疫佐剂使用有免疫增强效应。

关 键 词:Trop2  CD40L  病毒样颗粒疫苗

Expression,Purification and Activity Study on the Immune-Enhanced Trop2-CD40L Virus Like Particles
WANG Lin,WANG Xi,YANG Ming,LI Yan,DONG Ke,ZHANG Hui-zhong.Expression,Purification and Activity Study on the Immune-Enhanced Trop2-CD40L Virus Like Particles[J].Journal of Modern Laboratory Medicine,2016,0(4):1-4,9.
Authors:WANG Lin  WANG Xi  YANG Ming  LI Yan  DONG Ke  ZHANG Hui-zhong
Institution:Department of Clinical Research and Diagnosis, Tangdu Hospital of Fourth Military Medical University,Xi'an 710038,China
Abstract:Objective To construct the immune-enhanced Virus like Particles(VLPs)based on Trop2-CD40L fusion protein,which laid the foundation for the subsequent induction of humoral and cellular immune response.Methods Firstly,amplified a Trop2-CD40L fusion geneby the method of over-lapping PCR,then cloned the fusion gene into pFastbacTMshuttle vector(named as pFastbacTM/Trop2-CD40L).The constructed vectorwas then transformed into E.coli DH10Bac to build recombinant Trop2-CD40LBacmid.The rBV/Trop2-CD40L was obtained by transfection TN5 insect cells with the Trop2-CD40L Bacmid,and finally,the Trop2-CD40L VLPs was prepared by co-infection TN5 cells with rBV/Gag and rBV/Trop2-CD40L in a MOI ratio of 1:10.After large scale preparation, VLPs was concentrated and purified bysucrose density gradient centrifugation.Then WB detection,electron microscope and Cytokine ELISAwere performed to confirm the Trop2-CD40L VLPs production and it's in vitro biological activity(t=7.266,P<0.05).Results Successfully amplified the Trop2-CD40L fusion gene by the method of overlapping PCRand expressed and purified Trop2-CD40L chimeric VLPs by using the Bac-to-Bacbaculovirus expression system(SIV Gag was used as shell protein).Conclusion The Trop2-CD40L chimeric VLPs was successfully prepared,evidencing CD40L used as immune adjuvant immune activator,which established a fine theory and experiment basis for the further research.
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《现代检验医学杂志》浏览原始摘要信息
点击此处可从《现代检验医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号